Shandong Xinhua Pharmaceutical Company Limited

Symbol: 000756.SZ

SHZ

23.14

CNY

company-market-status

  • 33.7050

    P/E ratio

  • 4.3817

    PEG ratio

  • 12.18B

    Mrk Cap

  • 0.01%

    Div Yield

Акции в обращение

526.520029M

Притежавани от вътрешни лица

0.006%

Притежавани от институции

0.646%

  • Highest
    • 8.97
    • 7.16
    • 5.89
    • 5.66
    • 5.28
    • 5.70
    • 6.81
    • 7.62
    • 7.37
    • 6.99
    • 6.80
    • 6.46
    • 6.94
    • 7.25
    • 11.69
    • 9.53
    • 9.63
    • 10.06
    • 10.25
    • 9.07
    • 9.69
    • 9.14
    • 7.92
    • 8.32
    • 8.35
    • 8.90
    • 8.56
    • 8.07
    • 7.52
    • 8.70
    • 8.75
    • 9.76
    • 9.61
    • 33.98
    • 27.13
    • 21.09
    • 18.60
    • 19.45
    • 23.28
    • 27.95
    • 31.99
  • Lowest
    • 8.68
    • 6.94
    • 5.89
    • 5.50
    • 5.28
    • 5.54
    • 6.62
    • 7.25
    • 7.37
    • 6.87
    • 6.62
    • 6.46
    • 6.85
    • 7.25
    • 10.61
    • 9.53
    • 9.06
    • 9.75
    • 10.08
    • 9.07
    • 9.57
    • 9.14
    • 7.77
    • 8.17
    • 8.26
    • 8.76
    • 8.40
    • 7.90
    • 7.39
    • 7.91
    • 8.75
    • 9.53
    • 8.93
    • 29.77
    • 25.90
    • 20.26
    • 17.58
    • 17.50
    • 20.63
    • 27.41
    • 30.75

Информация за компанията

Последващ PE: Healthcare
Индустрия: Drug Manufacturers—Specialty & Generic
ГЛАВЕН ИЗПЪЛНИТЕЛЕН ДИРЕКТОР:Mr. Tongqing He
Служители на пълно работно време:6533
Град:Zibo
Адрес:Chemical Industry Area
IPO:1997-08-06
CIK:
Уебсайт:https://www.xhzy.com

Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.

Оборотен капитал

202220212020201920182017
Парични средства и инвестиции1158.74744.66855.77690.47778.42731.13
Приемници0.000.000.000.000.000.00
Инвентарна книга1211.991027.541124.361130.34951.72713.21
Други50.8044.59114.07102.89619.02565.65
Общо текущи активи3456.962753.962686.872428.392349.172009.99
Acc Payable1090.081066.39742.90798.51889.61738.29
Краткосрочен дълг835.48693.28623.04889.00841.64241.46
Други текущи пасиви1232.92742.211015.10798.00605.18499.09
Текущи пасиви3158.492501.882381.042485.512360.041490.84

Капиталова структура

Всички числа в милиони

Общо активи

1905,46 щ.д.

Общо задължения

523110175,15 щ.д.

Дългосрочен дълг

0,00 щ.д.

Парични средства и екви

503467118,60 щ.д.

Goodwill

0,00 щ.д.

Неразпределена печалба

214532093,12 щ.д.

Обикновени акции

669,63 щ.д.

Стойност на предприятието

19,03 щ.д.

Дивиденти за маса

ГодиниQ1Q2Q3Q4Общо
19980.0000.0000.0540.0000.054
19990.0000.0000.0150.0000.015
20000.0000.0000.0310.0000.031
20010.0000.0000.0620.0000.062
20020.0000.0000.0620.0000.062
20030.0000.0000.0460.0000.046
20040.0000.0000.0310.0000.031
20060.0000.0380.0000.0000.038
20070.0000.0000.0150.0000.015
20080.0000.0000.0230.0000.023
20090.0000.0000.0230.0000.023
20100.0000.0000.0380.0000.038
20110.0000.0000.0380.0000.038
20120.0000.0000.0230.0000.023
20130.0000.0080.0000.0000.008
20140.0000.0000.0150.0000.015
20150.0000.0000.0150.0000.015
20160.0000.0000.0150.0000.015
20180.0230.0000.0380.0000.062
20190.0000.0000.1000.0000.100
20200.0000.0000.1200.0000.120
20210.0000.0000.1500.0000.150
20220.0000.0000.1500.0000.150
Подобни запаси
Може да се интересувате и от
PILL.CN
Canntab Therapeutics Limited.
0.015 CAD
CNQ
CRON
Cronos Group Inc..
1.75 USD
NASDAQ
RMTI
Rockwell Medical, Inc..
3.32 USD
NASDAQ
ATNX
Athenex, Inc..
0.2031 USD
NASDAQ
SCYX
SCYNEXIS, Inc..
2.5 USD
NASDAQ
RDHL
RedHill Biopharma Ltd..
2.32 USD
NASDAQ
CPIX
Cumberland Pharmaceuticals Inc..
1.61 USD
NASDAQ
PRPH
ProPhase Labs, Inc..
9.49 USD
NASDAQ
OGI
OrganiGram Holdings Inc..
0.371 USD
NASDAQ
BOI.PA
Boiron SA.
37.9 EUR
EURONEXT

Frequently Asked Question

Why is your stock tool better than competitors?

Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms

Can I trust the data on your website and where do they come from?

Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.

Who creates the content on your website and is it approved by experts in finance and investing?

All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.

What problem does your tool solve? Who is the target audience for your tool

Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.

Why did you decide to create your tool?

While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.

What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?

Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee

Who is your team and do they have enough experience?

You can read about our team here, or you can contact us at [email protected] for more information.